FY2027 EPS Forecast for IceCure Medical Cut by Analyst

IceCure Medical Ltd (NASDAQ:ICCM) – Stock analysts at Brookline Capital Management reduced their FY2027 EPS estimates for shares of IceCure Medical in a research note issued on Tuesday, November 26th. Brookline Capital Management analyst K. Dolliver now expects that the company will earn $0.23 per share for the year, down from their previous forecast of $0.25. The consensus estimate for IceCure Medical’s current full-year earnings is ($0.27) per share. Brookline Capital Management also issued estimates for IceCure Medical’s FY2028 earnings at $0.33 EPS.

ICCM has been the topic of several other reports. HC Wainwright reissued a “buy” rating and set a $2.50 price target on shares of IceCure Medical in a research note on Wednesday. Alliance Global Partners upgraded IceCure Medical to a “strong-buy” rating in a research report on Friday, November 1st.

IceCure Medical Trading Up 5.8 %

ICCM opened at $0.83 on Thursday. IceCure Medical has a 1-year low of $0.48 and a 1-year high of $1.57. The stock has a market capitalization of $37.96 million, a PE ratio of -2.77 and a beta of 0.48. The company has a current ratio of 2.97, a quick ratio of 2.54 and a debt-to-equity ratio of 0.03. The firm has a 50-day moving average price of $0.65 and a two-hundred day moving average price of $0.73.

Institutional Trading of IceCure Medical

An institutional investor recently bought a new position in IceCure Medical stock. Renaissance Technologies LLC purchased a new position in shares of IceCure Medical Ltd (NASDAQ:ICCM) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund purchased 66,400 shares of the company’s stock, valued at approximately $49,000. Renaissance Technologies LLC owned 0.15% of IceCure Medical at the end of the most recent reporting period. Institutional investors and hedge funds own 0.62% of the company’s stock.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.